NVAX surged +20.65% to about $12.62 from a prior close of $10.46, rallying in premarket and extending gains through the regular session. Primary catalyst: the U.S. FDA conditionally approved Novavax's updated COVID-19 vaccine formulation targeting the latest XFG subvariant.

ALEC is trading up roughly +22.1% intraday, near $2.21 versus a prior close of $1.81. The move ignited in premarket trading, spiking more than +60% before fading into the regular session.

TWST is up +7.79% to $203.37 during Monday's regular session, touching a fresh 52-week high near $203.95. Primary catalyst: Anthropic tapped Twist Bioscience (alongside Adaptyv Bio) as an independent evaluator to produce and test AI-designed proteins across 15 targets.

The $3.60 central target is the arithmetic mean of four verified analyst price targets: $5.00 (H.C. Wainwright), $6.00 (BTIG), $2.00 (Morgan Stanley), and $1.50 (Mizuho). Based on Alector's October 2, 2026 close of $1.81, reaching $3.60 would require roughly a 99% advance — a very large move.

Lead candidate transition: AL137, an ABC-enabled anti-amyloid antibody for Alzheimer's disease, is targeting an IND (Investigational New Drug) filing in Q1 2027 and first-in-human dosing in Australia no later than April 2027. Near-term data catalyst: An independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101), partnered with GSK, could shape sentiment around the company's late-stage progranulin strategy.

ALEC is up +20.44% to $2.18, jumping from the prior session close of $1.81 during regular market hours. The catalyst is Alector's exclusive global licensing deal with Genentech (Roche) for its AL050 Parkinson's disease program.

ERNA is the common stock of Ernexa Therapeutics, a preclinical biotech advancing lead candidate ERNA-101 toward a planned fourth-quarter 2026 IND (Investigational New Drug) filing in platinum-resistant ovarian cancer. ERNAW is a listed warrant tied to the same issuer, carrying a $0.68 exercise price and a defined expiration, making it a leveraged, time-sensitive derivative rather than an equity position.

INSM is down roughly -8.43% (-$9.37) intraday to about $101.75 during regular trading, off its prior close of $111.12. Primary catalyst: longtime CFO Sara Bonstein announced she will step down on Oct. 30, a surprise exit that raised leadership-continuity concerns.

The $110 central target is the arithmetic mean of the verified analyst price targets reviewed, not a single firm's forecast. Following positive OPUS-1 Phase 3 data for VAX-31, shares jumped to a new 52-week high around $87–$89, requiring roughly a 26% gain to reach $110.

Near-term catalyst: Topline data from the pivotal OPUS-1 adult Phase 3 trial of VAX-31, the company's 31-valent PCV candidate, was presented in early October 2026, with follow-on Phase 3 readouts (OPUS-2 and OPUS-3) expected in the first half of 2027. Strategic positioning: VAX-31 is described by the company as the broadest-spectrum PCV candidate in the clinic today, targeting roughly 95% of invasive pneumococcal disease (IPD) serotypes in U.S. adults aged 50 and older.

PCVX is up +37.38% to $77.59 during Monday's regular session, after gapping sharply higher in premarket trading. The catalyst: positive topline Phase 3 OPUS-1 data for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.

The $8.00 target is the most widely cited public price objective for ICU, originating from a single named analyst at Maxim Group, not a multi-analyst consensus. ICU's analyst coverage is thin; the one current, attributable target is $8.00, set on May 14, 2026.

ICU shares fell about -23% during Monday's regular session, reversing the +25% spike logged at the Oct. 2 close. The pullback reflects profit-taking after last week's rally sparked by a late-breaking ASN Kidney Week presentation and new ICD-10-PCS billing codes for its SCD therapy.

Commercialization ramp: SeaStar Medical is scaling sales of QUELIMMUNE, its pediatric acute kidney injury (AKI) therapy, with the completed FDA enrollment requirement for the SAVE surveillance registry supporting broader real-world adoption. Adult AKI opportunity: The company's adult program, SCD-ADULT, holds FDA Breakthrough Device Designation, positioning it as the largest potential growth catalyst ahead of a pivotal pathway.

ALNY shares declined roughly 17% over the last 30 days, falling from about $266 in early September to near $220 by early October. The drop extends a broader slide of about 30% over the last quarter and more than 44% year-to-date.

FHTX is down -30.14% during Friday's regular session, extending Thursday's -18.21% slide and trading near $2.04, a new 52-week low. The sell-off follows Oct. 1 news that Foghorn and Eli Lilly will not advance cancer drug FHD-909 after Phase 1 data showed insufficient efficacy, ending their 2021 collaboration and a selective SMARCA2 degrader program.

The $4 central target is the arithmetic mean of four current, verifiable analyst price targets, which average roughly $4.25 before rounding. The latest verified closing price is about $2.92, meaning the target implies a roughly 37% upside.

FHTX shares are down -22.95% during regular market hours, trading near $2.25 after Thursday's collapse extended into Friday's session. Primary catalyst: Foghorn and Eli Lilly discontinued lead cancer asset FHD-909 after Phase 1 data showed insufficient efficacy, ending their collaboration including the SMARCA2 degrader program.

Pipeline reset underway: Foghorn's decision to discontinue the Lilly-partnered FHD-909 program refocuses the company on its wholly owned EP300, CBP, and ARID1B degrader candidates. Extended financial runway: A roughly 40% workforce reduction is expected to extend the company's cash runway into the second half of 2029.

PYXS is trading at $2.19, essentially flat (+0.00%) versus its prior close during the regular session, after an early premarket gain near +1.4% faded. Shares are consolidating after a sharp two-session slide of roughly -24% from $2.90 following a dilutive public offering priced at $2.90 per share.